| Status | Topic selection |
| Technology type | Medicine |
| Decision | Not selected |
| Reason for decision | Not eligible for Health Technology Evaluation guidance |
| Further information | The NICE-wide Prioritisation Board have concluded that the clear rationale to not evaluate this product is due to it being a paediatric licence extension of published HST20. NHS England will commission treatments for patients aged less than 18 years where specific commissioning conditions are met as per the Commissioning medicines for children in specialised services policy. |
| ID number | 12092 |
Email enquiries
- If you have any queries please email topic.selection@nice.org.uk
For further information on how we select topics for development, please see our page about topic selection